MedTrace Logo

Optimal Dose of Intravenous Oxycodone for Endotracheal Intubation

NCT02484352 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2017-07-21

No results posted yet for this study

Summary

Intravenous form of oxycodone is recently used for the adjunct of anesthetic agents to avoid adverse effects of the stimulation of endotracheal intubation. The potency ratio of oxycodone to fentanyl is not absolutely defined. The aim of this study was to assess the optimal dose of intravenous oxycodone for attenuation of hemodynamic responses to laryngoscopy and endotracheal intubation.

A prospective, randomized, double-blind study was conducted. Ninety one patients were randomly divided into 5 group based on the dose of oxycodone; 0, 0.05, 0.1, 0.15, 0.2 mg/kg. After giving each assigned dose of intravenous oxycodone, anesthesia was induced with thiopental and rocuronium. Heart rate (HR) and blood pressure (BP) was collected at baseline, before intubation, 1, 2, 3 minutes after intubation. The change of BP was calculated by (highest BP after intubation - baseline BP)/baseline BP.

Conditions

  • Intubation Complication
  • Blood Pressure

Interventions

DRUG

saline

different dosage of IV oxycodone was given before intubation

DRUG

0.05 mg/kg of oxycodone

different dosage of IV oxycodone was given before intubation

DRUG

0.1 mg/kg of oxycodone

different dosage of IV oxycodone was given before intubation

DRUG

0.15 mg/kg of oxycodone

different dosage of IV oxycodone was given before intubation

DRUG

0.2 mg/kg of oxycodone

different dosage of IV oxycodone was given before intubation

Sponsors & Collaborators

  • Chung-Ang University

    collaborator OTHER

  • Yong-Hee Park

    lead OTHER

Principal Investigators

  • Young-Cheol Woo, Ph.D. · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-10-31
Completion
2017-02-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02484352 on ClinicalTrials.gov